https://altamontpharma.com/team daily 0.75 2026-01-07 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512772415778-OBP8VPAMIZZK394GMY6W/Team_header.jpg Altamont Team https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1582670701627-TQLI3ZHPTQ6R0NTWTKXK/11.jpg Altamont Team - MARK E. PEARSON Chief Executive Officer & Portfolio Manager Mark is the Founder and CEO of Altamont Pharma Holdings as well as the Co-Founder and General Partner of Annex Ventures. Mark has been investing in startup Life Science and Technology companies for over 20 years. Mark is the Co-Founder and Vice Chairman of the Board of Drawbridge Realty, a San Francisco based real estate development and investment company, which owns over 6 million square feet of commercial real estate leased to Technology and Life Science companies predominantly in the western United States. Drawbridge Realty's portfolio exceeds $2.6 billion in asset value. In December 2014, Drawbridge Realty formed a partnership with international asset management firm Kohlberg Kravis Roberts & Co, LP (“KKR”) which made a significant investment in the company to substantially grow the platform. Mark is the Founder and CEO of Perceptive Real Estate Equities, Inc., a real estate development and investment company based in Dallas, TX with offices in Silicon Valley. Mark is the Co-Founder, lead investor and serves on the Board of Directors of Cessation Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Dallas, Texas with research laboratories in San Diego, California. Mark serves on the Board of Directors of The Scripps Research Institute in La Jolla, California, a world-renowned biomedical research institute employing over 2,400 scientists and support staff. Scripps Research Institute has created 80+ spin-off biotech companies, 15 FDA approved drugs, and currently has 30 drugs in its pipeline. Mark was the founding donor with a multimillion dollar gift establishing The Pearson Center for Addiction Research, which was founded in 2003 on The Scripps Research Institute campus in La Jolla, California by Mark Pearson, Dr. George Koob, Ph.D., and Dr. Barbara Mason, Ph.D. Mark earned his Bachelor of Science degree in Economics from the University of San Francisco and a Masters degree in Management from Stanford University Graduate School of Business where he was a Sloan Fellow. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1582670549925-76ABJUK2JUJA4XI3NO4H/8.jpg Altamont Team - YITAI TANG, Ph.D. Senior Investment Officer Yitai is an experienced biological scientist with a deep understanding in various fields within biomedical sciences, including neurodegenerative diseases, regenerative medicine and oncology. His research is published in top peer-reviewed journals. Prior to joining Altamont Pharma, Yitai was a postdoctoral scholar at Stanford University School of Medicine, where he combined stem cell biology and mouse genetics to study brain development and brain degeneration. He received comprehensive training in Regulatory affairs and Clinical Research at Stanford and University of California San Francisco. He was also actively involved with the Stanford Consulting Group (SCG). SCG investigates economic issues of concern to business or government entities and offers conceptual as well as analytical solutions. At Altamont Pharma, Yitai focuses on identifying and researching potential investments in companies in the oncology space as well as diseases of central nervous system. Yitai earned his Ph.D. in Biochemistry and Cell Biology from Rice University, Houston, Texas, where he proposed and experimentally verified novel models of tissue size regulation. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1582670293602-XI1XP1ALA57AA9C6WQNE/Unknown-1.jpg Altamont Team - PAUL BREMER, Ph.D. Senior Analyst Paul is a skilled medicinal chemist trained in the identification and development of bioactive molecules for therapeutic purposes. Specifically, he has extensive experience in the field of vaccines and immunotherapies for substance use disorders, and his innovative research has been published in numerous peer-reviewed journals. Paul is also our lead scientist at Cessation Therapeutics, a clinical stage biotech company focused on developing therapeutics designed to treat nicotine, opioid and other substance use disorders. Cessation Therapeutics is a startup that has been incubated and financed by Altamont Pharma. Paul earned his Bachelor of Arts in Chemistry from Colgate University and his Ph.D. in Medicinal Chemistry from Scripps Research Institute. Paul has previously held a scientist position at Vertex Pharmaceuticals. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1582670623115-X4JPWMT2M4HUGCLWYNNN/9.jpg Altamont Team - RHOZEL VARGAS Senior Vice President of Finance and Risk Management Rhozel is skilled in analyzing financial statements, budgeting, and handles various banking and operational activities for Altamont. Her biotechnology and real estate experience also equips her with the tools to conduct comprehensive analyses of the competitive landscape as it relates to the biotechnology industry. Rhozel earned her Bachelor of Science in Business Administration in Finance, with honors from California State Polytechnic University, Pomona. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/9544b057-de5c-452f-8405-3d24368ab65f/Erin+Davis.jpeg Altamont Team - ERIN M. DAVIS Senior Analyst Erin is a skilled laboratory biologist with a background in molecular biology and genetics as well as human anatomy and physiology. At Altamont, she analyzes potential profile companies for scientific rigor. Erin’s academic research was focused on cell signaling and epigenetics. Her most recent work used these approaches to detail nuclear hormone receptor activation and to explore the epigenetic regulation of neuroendocrine enzyme transcription in vivo. Erin earned her Bachelor of Science in Biological Science from the University of Cincinnati and her Master of Science in Biological Science from Portland State University. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1582675354263-ZPS86N3VCITJM1EXU3T3/13.jpg Altamont Team - YUAN LIN, Ph.D. Senior Analyst Yuan is an experienced biological scientist. Yuan has deep understanding and hands-on experience in various fields in the biopharmaceutical industry, including oncology, neurodegenerative diseases and protein engineering. His research is published in top peer-reviewed journals and is highly recognized with more than 300 citations. Yuan served as a postdoctoral scholar at Stanford University School of Medicine, where he combined structural biology and protein engineering approaches to create novel antibodies against cancer-related membrane receptors as potential therapeutics. Yuan earned his Bachelor of Science in Biological Science from Peking University (China), where he participated in research on the molecular mechanism of innate immunity. He then earned a Ph.D. in Molecular Biophysics from the University of Texas Southwestern Medical Center, where he discovered the phase separation phenomenon of RNA-binding proteins and demonstrated how this may contribute to neurodegenerative diseases. https://altamontpharma.com/portfolio daily 0.75 2026-03-10 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512772383798-PYZKVC658N3KS45V59QJ/Portfolio_header.jpg Portfolio https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/215014b6-6e25-46d1-b4df-5754be745eac/ACIU.png Portfolio - AC Immune SA (NASDAQ: ACIU) is clinical-stage biopharmaceutical company, is a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and certain rare indications. Lausanne, Switzerland https://www.acimmune.com/ https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/0f994d85-4508-4a94-b9fa-5ffaab541874/Alkermes.jpg Portfolio - ALkermes plc (NASDAQ: ALKS) is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Dublin, Ireland https://www.alkermes.com/ https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/f9a6743d-0271-4357-aa57-ff2784f0cda9/ALMS.png Portfolio - ALUMIS Inc. (NASDAQ:alms) Achilles Therapeutics plc (NASDAQ: ACHL) https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1586991898529-OOVBZP5J562GG1GAQE27/Amygdala.jpeg Portfolio - Amygdala neurosciences is focused on addressing the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction. San Francisco, CA http://www.amygns.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/0d8dd290-f756-4851-a847-8abbeae76029/ANAB.png Portfolio - AnaptysBio, Inc. (Nasdaq: anab) is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. San Diego, CA https://www.anaptysbio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1628272573879-KL75HFBAT2P7NWZOM53C/Autolus-logo-for-website.jpg Portfolio - Autolus Therapeutics Plc (NASDAQ: AUTL) AUTOLUS THERAPEUTICS, INC (NASDAQ: AUTL) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.. London, UK https://www.autolus.com/ https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/a878ad55-2960-4e90-bf9f-bd67207aa78a/axsome.png Portfolio - Axsome Therapeutics, Inc (NASDAQ: AXSM) is commercial-stage biopharmaceutical company developing and delivering novel therapies for central nervous system, or CNS, conditions that have limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. New Yorrk, NY https://www.axsome.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/5b9b3acf-b0c9-4c8d-b085-788094963496/CLDX.png Portfolio - Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Hampton, NJ https://www.celldex.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/484fa3de-f77f-4655-b700-99426c6f4f97/Cessation_logo_2022+%281%29.jpg Portfolio - Cessation therapeutics, INC is a clinical stage company focused on research and development of therapeutics designed to treat nicotine, opioid and other substance use disorders. Dallas, TX https://www.cessationtherapeutics.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/4579fb83-d714-40ee-8778-f2092c302694/images+%281%29.png Portfolio - Compass Therapeutics, inc. (NASDAQ: cmpx) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Boston, MA https://www.compasstherapeutics.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1586992814745-2C097ZIT0W0YFPW7FR5B/corvus.png Portfolio - CORVUS PHARMACEUTICALS, INC (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. Burlingame, CA http://www.corvuspharma.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1629821461300-96HTZ0X34S8TLJTFSHA8/Dialectic.jpg Portfolio - DIALECTIC THERAPEUTICS, INC is a biotechnology company dedicated to the development of unique, impactful anti-cancer drugs that effectively treat patients with few to no other options. Dallas, TX https://www.dtsciences.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/f5cb75a1-8a9d-4263-ae6f-20da6553e221/IVA.png Portfolio - Inventiva S.A. (NASDAQ: IVA) is clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. France https://inventivapharma.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/0559bc53-1fab-415e-ab8f-98b75befca76/Screen+Shot+2023-08-11+at+4.39.38+PM.png Portfolio - IO Biotech, Inc (NASDAQ: IOBT) is a clinical-stage biotechnology company dedicated to the identification and development of disruptive immune therapies for the treatment of cancer. Copenhagen, Denmark https://iobiotech.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/58e29915-2004-4fc6-9757-b98041ff257d/Iovance.jpeg Portfolio - IOVANCE Biotherapeutics, Inc (NASDAQ: IOVA) is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. San Carlos, CA https://www.iovance.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/3d2c59bd-9fd7-4a80-9f55-0c8b59235f40/Meira.jpg Portfolio - MeiragTx HOldings plc (Nasdaq: MGTX) is a clinical-stage gene therapy company focused on developing treatments for patients with serious diseases. New York, NY https://meiragtx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/c48e474a-e33c-4dfb-b247-9c8371c0e809/Personalis.jpg Portfolio - Personalis, Inc (NASDAQ: PSNL) is a cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. Menlo Park, CA https://www.personalis.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/cca52501-eaa2-411d-9372-141e4116946a/Praxis.jpeg Portfolio - Praxis Precision Medicines, INc (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. Boston, MA https://praxismedicines.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1570642426981-YYGNBZUHZFF3Y88L26MA/Regenxbio+Logo.png Portfolio - Regenxbio, Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Rockville, MD https://www.regenxbio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/af6538e0-2718-4efb-93b9-d7f125f4be57/Ribo.jpeg Portfolio - RIBOSCIENCE LLLC applies specialized chemistry and biology to create novel treatments for human diseases. Sunnyvale, CA https://www.riboscience.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/505f0024-138f-4c89-bc9e-3b2c9664b99c/SVRA.png Portfolio - Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Langhorne, PA https://www.savarapharma.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/c7dcf66d-d92a-4534-a204-75b244bcef9c/Solid_Biosciences.jpg Portfolio - Solid Biosciences, INc (NASADAQ: SLDB) is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne Muscular Dystrophy. Cambridge, MA https://www.solidbio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/7ac4bb7f-2370-4ed8-ac64-3d5429a5d94f/ventyx.jpeg Portfolio - Ventyx Biosciences, Inc (NASDAQ: VTYX) is clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Ventyx is currently being acquired by Eli Lilly for up to $1.2 billion. San Diego, CA https://ventyxbio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/8f253b35-2193-48d9-8327-b2f107b01fa9/SRRK.png Portfolio - SCHOLAR ROCK HOLDING CORP (NASDAQ: SRRK) is a biopharmaceutical company combining bold science with a deep commitment to make a meaningful difference for people living with serious diseases.. Cambridge, MA https://scholarrock.com/ https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/a0bd3d87-e219-4cb6-a9b1-1f6db9dd62c6/UPB.jpg Portfolio - Upstream Bio, Inc. (NASDAQ: upb) is focused on developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Since its inception, the Company has devoted substantially all of its efforts to raising capital and incurring research and development expenses related to advancing verekitug, a clinical-stage monoclonal antibody that targets and inhibits the Thymic Stromal Lymphopoietin receptor. Waltham, MA https://upstreambio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/dd93cb71-5644-4e31-95bb-1e23446c6108/white.jpg Portfolio - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/dd93cb71-5644-4e31-95bb-1e23446c6108/white.jpg Portfolio - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1633471373119-8V4BYWSGTWR3L59Q38UD/achilles-logo.png Portfolio - Achilles Therapeutics plc (NASDAQ: ACHL) is a biopharmaceutical company developing precision T cell therapies that target clonal neoantigens. London, UK https://achillestx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/902864e6-87e0-4f1d-84d2-652fa45a4bc6/AKERO.jpeg Portfolio - Akero Therapeutics, INc. (NASDAQ: AKRO) is a clinical-stage company dedicated to developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis, or MASH, formerly known as non-alcoholic steatohepatitis, or NASH, a disease without any approved therapies. Akero was acquired by Novo Nordisk for up to $5.2 billion in December 2025. South San Francisco, CA https://akerotx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/fe96301c-e922-426c-8d59-39bf5d263685/ALLK.png Portfolio - Allakos Inc (Nasdaq: allk) is a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. San Carlos, CA https://www.allakos.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1576524363898-SNHVKDAWU9NOJTDPV2YI/ARDX_logo.png Portfolio - ARDELYX, INC (NASDAQ: ARDX) is committed to bringing effective medicines with distinct safety and dosing advantages to underserved patients by using the gut as the gateway to better health. Fremont, CA https://www.ardelyx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1603918045098-N9Q4C4SISABX26Y0ZBAY/CARA.png Portfolio - CARA THERAPEUTICS, INC (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Stamford, CT https://www.caratherapeutics.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1576524467353-Z5S706LHKKU99NFVRROD/CCXI_logo.jpeg Portfolio - chemocentryx, inc (nasdaq: CCXI) is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. ChemoCentryx was acquired by Amgen for $4 billion in October 2022. San Carlos, CA https://www.chemocentryx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1588292727658-J66LMK1N8V7QJ5SUNF5E/Screen+Shot+2020-04-30+at+5.25.07+PM.png Portfolio - CONTRAFECT CORPORATION (NASDAQ: CFRX) is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Yonkers, NY https://www.contrafect.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/cb153b46-46ee-41c0-a20b-c4a410f41a06/CBAY.jpg Portfolio - CymaBay Therpaeutics, Inc (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay was acquired by Gilead for $4.3 billion in March 2024. Newark, CA https://www.cymabay.com/ https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/74b02253-096f-4818-8121-69d878980603/CytomX_logo.jpg Portfolio - CYTOMX Therapeutics, Inc (NASDAQ: CTMX) https://cytomx.com/ https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1628272533867-WM4CCWU3MDFBNZ8C2W7S/7083f096-c340-44af-8ae9-7cc9c6b303ef-1562846569920.png Portfolio - Deciphera Pharmaceuticals, INC (NASDAQ: DCPH) is developing novel drug candidates to improve the lives of cancer patients by addressing key mechanisms of tumor and drug resistance that limit the effectiveness of many cancer therapies. Deciphera was acquired by ONO Pharmaceutical Co, Ltd. for $2.4 billion in June 2024. Waltham, MA https://www.deciphera.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1559939909095-KGFUDOXG8E2CMF1NIP0K/fate.jpg Portfolio - FATE THERAPEUTICS, INC (NASDAQ: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. San Diego, CA http://www.fatetherapeutics.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/faea0d03-16d4-48e7-97ce-df7ae2ab0554/Galera.jpg Portfolio - Galera Therapeutics, Inc (NASDAQ: GRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. Malvern, PA https://www.galeratx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623484755-HHZ5J2N43KYLD3X5Z8C1/heron.jpg Portfolio - HERON Therapeutics, INC (NASDAQ: HRTX) aims to build on therapeutics with well-known pharmacology by improving their safety and efficacy as well as broadening their potential field of use. San Diego, CA https://www.herontx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1559939856339-DEF08UDXXB30B86P8WDZ/Screen%2BShot%2B2019-06-07%2Bat%2B1.35.36%2BPM.jpg Portfolio - IMMUNE DESIGN CORP (NASDAQ: IMDZ) is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. Immune Design was acquired by Merck for $300 million in April 2019. Seattle, WA http://www.immunedesign.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1601484350352-NJ92PRKIUCNXF9UF42DQ/inflaRx+Logo+1500x477.png Portfolio - Inflarx n.v. (NASDAQ: IFRX) INFLARX N.V. (NASDAQ: IFRX) is developing new first-in-class therapeutics targeting acute and chronic inflammation. Jena, Germany http://www.inflarx.de https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1577734389802-IL56TXLBWV66EXAB1DPN/ITCI-logo.jpeg Portfolio - Intra-Cellular Therapies Inc (NASDAQ: ITCI) is focused on developing innovative treatments to improve the lives of individuals suffering from neuropsychiatric and neurologic disorders, in order to reduce the burden on patients and their caregivers. Intra-Cellular was acquired by Johnson & Johnson for $14.6 billion in April 2025. New York, NY https://www.intracellulartherapies.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/69eaf5e5-2bcd-45e4-a650-0198081f1dc4/ISEE.jpg Portfolio - Iveric BIO, Inc (NASDAQ: ISEE) is a biotechnology company engaged in the research and development of therapeutics to slow, halt, or reverse diseases of aging. South San Francisco, CA https://unitybiotechnology.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1540426464395-O4WA7JWXB8B4X7YSGFV6/jounce+4.png Portfolio - Jounce therapeutics, Inc (NASDAQ: JNCE) is focused on developing unparalleled immunologic insights into tumors in order to match the right therapies to the right patients. Cambridge, MA https://www.jouncetx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1581363304289-IIK5G97KH38GWFKQDK6Q/image-asset.png Portfolio - KADMON Holdings, INC (NYSE: KDMN) is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Kadmon was acquired by Sanofi (NASDAQ:SNY) for $1.9 Billion. New York, NY https://kadmon.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/f905e5c8-5d6e-49c3-af5d-8d3ef9497356/krystal.jpg Portfolio - Krystal Biotech, Inc (NASDAQ: KRYS) Marker Therapeutics, Inc (NASDAQ: MRKR) https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/52aaf5c7-660f-4d2b-b6dd-6661ef185a0d/Mirati_Therapeutics_Inc___Logo.jpg Portfolio - Mirati Therapeutics, inc (Nasdaq: mrtx) is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Mirati was acquired by Bristol Myers Squibb for up to $5.8 million in January 2024. San Diego, CA https://www.mirati.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623513752-FQ6XXBO7NU14JA3WKX51/monogram.jpg Portfolio - MONOGRAM BIOSCIENCES, INC (NASDAQ: MGRM) (FORMERLY VIROLOGIC, INC) blends the high-quality pathology of academic-based centers with the personal service of a local pathologist. Monogram was acquired by LabCorp for $107 million In June 2009. South San Francisco, CA https://www.monogrambio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623436402-ZVAGT2P8CXA2OXCO8EBR/novak.jpg Portfolio - NOVAVAX, INC (NASDAQ: NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Gaithersburg, MD http://www.novavax.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/e320f79d-556f-4690-b34a-f4359f1a90f5/Orchard.png Portfolio - Orchard Therpaeutics plc (NASDAQ: ORTX) is a global gene therapy company dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. Orchard was acquired by Kyowa Kirin for up to $478 million in January 2024. London, United Kingdom https://www.orchard-tx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1542074285672-3U0LCMAPEBG1U5UVX1SB/pliant_logo2.jpg Portfolio - Pliant therapeutics, inc (NASDAQ: PLRX) is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. South San Francisco, CA http://www.pliantrx.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1625719211151-E7UQWNS4380FH619P8HK/Provention+Bio.PNG Portfolio - Provention bio, inc. (NASDAQ: prvb) is a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases. Provention Bio has been acquired by Sanofi for $2.9 billion in April 2023. Red Bank, NJ http://www.proventionbio.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/5740a2cb-b6f1-4fa3-8a10-3ec094187264/Puma+Bio.jpeg Portfolio - Puma Biotechnology, Inc (NASDAQ: PBYI) is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. Los Angeles, CA https://www.pumabiotechnology.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623541042-GFVDBEAEKI1KT22LNI4V/raptor.jpg Portfolio - RAPTOR PHARMACEUTICALS CORP (NASDAQ: RPTP) is focused on identifying and developing differentiated and accessible medicines that address unmet medical needs. Raptor was acquired by Horizon Pharma or $800 million in October 2016. Novato, CA http://www.horizonpharma.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623552372-8NKWHL3Z6FGDR3M2NKH2/relypsa.jpg Portfolio - RELYPSA, INC (NASDAQ: RLYP) is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was acquired by Galencia for $1.5 billion in September 2016. Redwood City, CA http://www.relypsa.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/7fe5840c-105e-4914-8870-7b075d066942/Silverback.jpg Portfolio - Silverback therapeutics, inc (NASDAQ: SBTX) s a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623471402-H6VVBQY21E3XAMD5O1JS/StemCentrx.jpg Portfolio - STEMCENTRIX, INC is dedicated to making a remarkable impact for cancer patients. Stemcentrx develops therapies and diagnostics for cancer patients. Stemcentrx was acquired by AbbVie for $5.8 billion in 2016. South San Francisco, CA https://www.abbvie.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/23c830fb-16cf-4931-89fa-06ac3817e0e6/TCR2+1.png Portfolio - TCR² Therapeutics, Inc (NASDAQ: TCRR) is a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. TCR² was acquired by Adaptimmune Therapeutics in June 2023. Cambridge, MA https://www.tcr2.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1585952382359-XTXNZVSCOCHMJKP163J4/urogen.jpeg Portfolio - Urogen Pharma, ltd (NASDAQ: URGN) is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. Princeton, NJ https://www.urogen.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/7d627756-e352-43d0-ba5d-ec244dc4c098/Verona.png Portfolio - Verona Pharma plc (NASDAQ: VRNA) is a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Verona was acquired by Merck in October 2025 for $10 billion. London, UK https://www.veronapharma.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512623526145-PQSTU073I908DDNGE2DX/xenoport.jpg Portfolio - XENOPORT, INC (NASDAQ: XNPT) is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Xenoport was acquired by Arbor Pharmaceuticals, LLC for $467 million in July 2016. Santa Clara, CA http://www.arborpharma.com https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1559938952937-05E5E8ECEVUE75PYJFLT/xeris-logo-og.jpg Portfolio - XERIS PHARMACEUTICALS, INC (NASDAQ: XERS) is dedicated to the development of ready-to-use, room-temperature stable injectable and infusible drug formulations that offer distinct advantages over conventional product formulations. Chicago, IL https://www.xerispharma.com https://altamontpharma.com/disclaimer daily 0.75 2017-12-08 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512584513039-VAKFVQG26J00FXW5H1LU/smallrectang4.jpg disclaimer https://altamontpharma.com/contact daily 0.75 2025-06-16 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/51fe0c2c-8b58-4bb2-9822-0caa92f14171/smallrectang4.jpg Contact https://altamontpharma.com/online-privacy-policy daily 0.75 2021-10-06 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512584513039-VAKFVQG26J00FXW5H1LU/smallrectang4.jpg Online Privacy Policy https://altamontpharma.com/home daily 1.0 2025-06-16 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512620215795-E3LM8C1B7MMNDKV06R3N/Finance_home.jpg Home https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771310025-UH9NAU31T4XPGWGH9MDL/About_square+copy.jpg Home PORTFOLIO https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771331370-XCDGKFEXWXXU14VQYF1R/Portfolio_square.jpg Home TEAM https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771348532-441JATZZC3F9V902KUG5/Team_square.jpg Home NEWS https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771376502-TD6ZVJ0GEMLY6OGY5M1F/News_square.jpg Home CONTACT https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1519846724510-I5HVIP3FRBOU15HN7Y1G/altamont_homesquare6.jpg Home https://altamontpharma.com/about daily 0.75 2023-09-22 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512772354105-N16VMWLCJDF6SDA63ZJ0/About_header.jpg About https://altamontpharma.com/news daily 0.75 2026-01-20 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512772458924-JGRZMVTXZ6W31IG47QIF/News_header.jpg News https://altamontpharma.com/terms-and-conditions daily 0.75 2019-04-03 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512584513039-VAKFVQG26J00FXW5H1LU/smallrectang4.jpg Terms and Conditions https://altamontpharma.com/home-copy-2nd-design daily 0.75 2023-09-25 https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512620215795-E3LM8C1B7MMNDKV06R3N/Finance_home.jpg Home (Copy 2nd design) https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771310025-UH9NAU31T4XPGWGH9MDL/About_square+copy.jpg Home (Copy 2nd design) PORTFOLIO https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771331370-XCDGKFEXWXXU14VQYF1R/Portfolio_square.jpg Home (Copy 2nd design) TEAM https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771348532-441JATZZC3F9V902KUG5/Team_square.jpg Home (Copy 2nd design) NEWS https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1512771376502-TD6ZVJ0GEMLY6OGY5M1F/News_square.jpg Home (Copy 2nd design) CONTACT https://images.squarespace-cdn.com/content/v1/5a258b8451a58456ea4fbd04/1519846724510-I5HVIP3FRBOU15HN7Y1G/altamont_homesquare6.jpg Home (Copy 2nd design) https://altamontpharma.com/moodboard-jasper daily 0.75 2025-05-12 https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1461605452797-QA7MI71TS32XTRI3GVOU/Untitled-1.jpg Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1461619355997-ZAV09MWPDQNH86LHF90N/untitled.jpeg Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1461620489237-QAQ6U7KEO5III0AYUIFS/get-real.jpg Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1461618928008-H5L4OM00O8XDG5SFFWXY/7.jpg Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1461618408530-Y4QZHI2APVIJMRFUG8Q7/crop.jpg Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1464031021138-YBETCAKP0EZE4GN5QP20/pareidolia.jpg Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1464033164561-OWERNGEYR0AKBOTZVETB/Untitled-2.png Moodboard https://images.squarespace-cdn.com/content/v1/56f96a558a65e2431339cdaf/1464033301507-TSX1XY70Q79O991CW3GM/Screen+Shot+2015-03-09+at+4.21.13+PM.png Moodboard